Donga Socio Holdings (000640) - Total Assets
Based on the latest financial reports, Donga Socio Holdings (000640) holds total assets worth ₩2.13 Trillion KRW (≈ $1.44 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Donga Socio Holdings (000640) net assets for net asset value and shareholders' equity analysis.
Donga Socio Holdings - Total Assets Trend (2000–2024)
This chart illustrates how Donga Socio Holdings's total assets have evolved over time, based on quarterly financial data.
Donga Socio Holdings - Asset Composition Analysis
Current Asset Composition (December 2024)
Donga Socio Holdings's total assets of ₩2.13 Trillion consist of 22.1% current assets and 77.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 5.8% |
| Accounts Receivable | ₩124.93 Billion | 6.2% |
| Inventory | ₩183.56 Billion | 9.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩88.90 Billion | 4.4% |
| Goodwill | ₩50.62 Billion | 2.5% |
Asset Composition Trend (2000–2024)
This chart illustrates how Donga Socio Holdings's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Donga Socio Holdings (000640) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Donga Socio Holdings's current assets represent 22.1% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 5.8% of total assets in 2024, up from 3.3% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is inventory at 9.0% of total assets.
Donga Socio Holdings Competitors by Total Assets
Key competitors of Donga Socio Holdings based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Donga Socio Holdings - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.75 | 0.70 | 0.94 |
| Quick Ratio | 0.75 | 0.43 | 0.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-174.33 Billion | ₩-192.96 Billion | ₩-22.29 Billion |
Donga Socio Holdings - Advanced Valuation Insights
This section examines the relationship between Donga Socio Holdings's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.60 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 3.7% |
| Total Assets | ₩2.03 Trillion |
| Market Capitalization | $427.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values Donga Socio Holdings's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Donga Socio Holdings's assets grew by 3.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Donga Socio Holdings (2000–2024)
The table below shows the annual total assets of Donga Socio Holdings from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩2.03 Trillion ≈ $1.38 Billion |
+3.75% |
| 2023-12-31 | ₩1.96 Trillion ≈ $1.33 Billion |
+13.03% |
| 2022-12-31 | ₩1.73 Trillion ≈ $1.17 Billion |
+2.37% |
| 2021-12-31 | ₩1.69 Trillion ≈ $1.15 Billion |
+11.93% |
| 2020-12-31 | ₩1.51 Trillion ≈ $1.02 Billion |
+11.23% |
| 2019-12-31 | ₩1.36 Trillion ≈ $920.69 Million |
+9.39% |
| 2018-12-31 | ₩1.24 Trillion ≈ $841.64 Million |
-14.90% |
| 2017-12-31 | ₩1.46 Trillion ≈ $989.05 Million |
+4.08% |
| 2016-12-31 | ₩1.40 Trillion ≈ $950.26 Million |
+14.61% |
| 2015-12-31 | ₩1.22 Trillion ≈ $829.16 Million |
+13.18% |
| 2014-12-31 | ₩1.08 Trillion ≈ $732.63 Million |
+9.39% |
| 2013-12-31 | ₩988.28 Billion ≈ $669.74 Million |
-42.65% |
| 2012-12-31 | ₩1.72 Trillion ≈ $1.17 Billion |
+15.39% |
| 2011-12-31 | ₩1.49 Trillion ≈ $1.01 Billion |
+20.98% |
| 2010-12-31 | ₩1.23 Trillion ≈ $836.45 Million |
+16.74% |
| 2009-12-31 | ₩1.06 Trillion ≈ $716.50 Million |
+37.32% |
| 2008-12-31 | ₩769.94 Billion ≈ $521.78 Million |
+7.88% |
| 2007-12-31 | ₩713.72 Billion ≈ $483.68 Million |
-2.46% |
| 2006-12-31 | ₩731.74 Billion ≈ $495.89 Million |
+1.03% |
| 2005-12-31 | ₩724.29 Billion ≈ $490.84 Million |
+2.59% |
| 2004-12-31 | ₩706.01 Billion ≈ $478.45 Million |
+2.11% |
| 2003-12-31 | ₩691.41 Billion ≈ $468.56 Million |
+17.05% |
| 2002-12-31 | ₩590.72 Billion ≈ $400.32 Million |
-0.49% |
| 2001-12-31 | ₩593.63 Billion ≈ $402.30 Million |
+8.45% |
| 2000-12-31 | ₩547.36 Billion ≈ $370.94 Million |
-- |
About Donga Socio Holdings
Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of S… Read more